Traders looking ahead to the additional fiscal stimulus and other government spending
|Bid||0.8600 x 0|
|Ask||0.8800 x 0|
|Day's Range||0.8600 - 0.8800|
|52 Week Range||0.2500 - 2.0100|
|Beta (5Y Monthly)||0.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar. 16, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.25|
RICHMOND HILL, ON / ACCESSWIRE / January 13, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, wishes to confirm that it is not aware of any material, undisclosed information related to the Company that would account for the recent increase in the market price and level of trading volume of its ordinary shares.
RICHMOND HILL, ON / ACCESSWIRE / December 30, 2020 / Helix BioPharma Corp.
RICHMOND HILL, ON / ACCESSWIRE / December 22, 2020 / Helix BioPharma Corp.